Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 394-402 , June 2010

Smoking outcome by psychiatric history after behavioral and varenicline treatment

  • Jennifer B. McClure, Ph.D.

      Affiliations

    • Group Health Research Institute, Seattle, WA 98101, USA
    • Corresponding Author InformationCorresponding author. Group Health Research Institute, 1730 Minor Ave., Suite 1600, Seattle, WA 98101, USA. Tel.: +1 206 287 2737; fax: +1 206 287 2871.
    • ,
  • Gary E. Swan, Ph.D.

      Affiliations

    • SRI International, Menlo Park, CA 94025, USA
    • ,
  • Sheryl L. Catz, Ph.D.

      Affiliations

    • Group Health Research Institute, Seattle, WA 98101, USA
    • ,
  • Lisa Jack, M.A.

      Affiliations

    • SRI International, Menlo Park, CA 94025, USA
    • ,
  • Harold Javitz, Ph.D.

      Affiliations

    • SRI International, Menlo Park, CA 94025, USA
    • ,
  • Tim McAfee, M.D., M.P.H.

      Affiliations

    • Free & Clear, Inc., Seattle, WA 98104, USA
    • ,
  • Mona Deprey, M.S.

      Affiliations

    • Free & Clear, Inc., Seattle, WA 98104, USA
    • ,
  • Julie Richards, M.P.H.

      Affiliations

    • Group Health Research Institute, Seattle, WA 98101, USA
    • ,
  • Susan M. Zbikowski, Ph.D.

      Affiliations

    • Free & Clear, Inc., Seattle, WA 98104, USA

Received 9 November 2009 ,Revised 25 January 2010 ,Accepted 9 March 2010.

References 

  1. Alhatem F, Black JE. Varenicline-induced mania in a bipolar patient. Clinical Neuropharmacology. 2009;32:117–118
  2. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological). 1995;57(1):289–300
  3. Benajmini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annals of Statistics. 2001;29:1165–1188
  4. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2008;(3. Art No: CD006103)
  5. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behavioral Science. 1974;19:1–15
  6. Diaz FJ, James D, Botts S, Maw L, Susce MT, de Leon J. Tobacco smoking behaviors in bipolar disorder: A comparison of the general population, schizophrenia, and major depression. Bipolar Disorders. 2009;11:154–165
  7. DiPaula BA, Thomas MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy. 2009;29:852–857
  8. Fagerstrom K, Aubin HJ. Management of smoking cessation in patients with psychiatric disorders. Current Medical Research and Opinions. 2009;25:511–518
  9. FDA . Varenicline (marketed as Chantix) information. 2008;Retrieved June 9, 2008, from http://www.fda.gov/cder/drug/infopage/varenicline/
  10. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008;
  11. Freedman R. Exacerbation of schizophrenia by varenicline. American Journal of Psychiatry. 2007;164:1269
  12. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association. 2006;296:47–55
  13. Gonzalez-Pinto A, Gutierrez M, Ezcurra J, Aizpuru F, Mosquera F, Lopez P, et al. Tobacco smoking and bipolar disorder. Journal of Clinical Psychiatry. 1998;59:225–228
  14. Haas AL, Munoz RF, Humfleet GL, Reus VI, Hall SM. Influences of mood, depression history, and treatment modality on outcomes in smoking cessation. Journal of Consulting and Clinical Psychology. 2004;72:563–570
  15. Hall SM, Prochaska J. Treatment of smokers with co-occurrring disorders: Emphasis on integration in mental health and addiction treatment settings. Annual Review of Clinical Psychology. 2009;5:409–431
  16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for nicotine dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction. 1991;86:1119–1127
  17. Hitsman B, Borelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: A meta-analysis. Journal of Consulting and Clinical Psychology. 2003;71:657–663
  18. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Journal of the American Medical Association. 2006;296:56–63
  19. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51:8–19
  20. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. American Journal of Psychiatry. 2007;164:1269–1270
  21. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. Journal of the American Medical Association. 2008;299:1121–1122
  22. Kuehn BM. Varenicline gets stronger warnings about psychiatric problems, vehicle crashes. Journal of the American Medical Association. 2009;302:834
  23. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association. 2000;284:2606–2610
  24. McClure JB, Swan GE, Jack L, Catz SL, Zbikowski SM, McAfee TA, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. Journal of General Internal Medicine. 2009;24(5):563–569
  25. McFall M, Saxon AJ, Thompson CE, Yoshimoto D, Malte C, Straits-Troster K, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. American Journal of Psychiatry. 2005;162:1311–1319
  26. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine. 2006;166:1561–1568
  27. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine. 2006;166:1571–1577
  28. Pirmoradi P, Roshan S, Nadeem SS. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. American Journal of Health-System Pharmacy. 2008;65:1624–1626
  29. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a ptient with a past history of depression. CNS Spectrums. 2008;13:511–514
  30. Regier DA, Farmer ME, Rae DS, Myers JK, Kramer M, Robins LN, et al. One-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic Catchment Area study. Acta Psychiatrica Scandinavica. 1993;88:35–47
  31. Rohde P, Lewinsohn PM, Brown RA, Gau JM, Kahler CW. Psychiatric disorders, familiar factors and cigarette smoking: I. Associations with smoking initiation. Nicotine & Tobacco Research. 2003;5:85–98
  32. Smith RC, Lindenmayer JP, Davis JM, Cronwell J, Noth K, Gupta S, et al. Cognitive and anit-smoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 2009;110:149–155
  33. Swan GE, Jack LM, Curry S, Chorost M, Javitz H, McAfee T, et al. Bupropion SR and counseling for smoking cessation in actual practice: Predictors of outcome. Nicotine & Tobacco Research. 2003;5:911–921
  34. Swan GE, Jack LM, Javitz HS, McAfee T, McClure JB. Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation. CNS Drugs. 2008;22:239–256
  35. Swan, G. E., McClure, J. B., Zbikowski, S., McAfee, T., Jack, L., Catz, S., et al. (in press). Behavioral counseling and varenicline treatment for smoking cessation American Journal of Preventive Medicine.
  36. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. Journal of the American Medical Association. 2006;296:64–71
  37. U.S. Department of Health and Human Services . Mental health: A report of the surgeon general. Rockville, MD: U.S. Department of Health and Human Services, Substance Abise and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999;
  38. Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research Opinion. 2007;23:793–801
  39. Ziedonis DM, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Adurain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine & Tobacco Research. 2008;10:1691–1715

PII: S0740-5472(10)00068-1

doi: 10.1016/j.jsat.2010.03.007

Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 394-402 , June 2010

Article Tools

* Image Usage & Resolution